EUVIMEDEUVIMED entdecken
Crossref

Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Indian women: a Markov microsimulation model analysis

Lakshmi Nagendra, Manju Chandran, Jean-Yves Reginster, Sanjay Kumar Bhadada, Saptarshi Bhattacharya, Deep Dutta, Mickael Hiligsmann

Osteoporosis International · 2025-02 · 36 (2) · 311-322

DOI: 10.1007/s00198-024-07328-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Osteoporosis International, online erschienen am 27.12.2024. Verfasst von Lakshmi Nagendra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, Karnataka, India. drlakshminagendra@gmail.com. Hauptthemen laut MEDLINE: Osteoporotic Fractures, Bone Density Conservation Agents, Alendronate, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Endocrine society of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A cost-effectiveness analysis of FRAX® intervention thresholds (ITs) in Indian women over 50 years indicated that generic alendronate was cost-effective for age-dependent major osteoporotic fracture (MOF) ITs and hip fracture (HF) ITs starting at ages 60 and 65 years for full and real-world adherence, respectively. Alendronate was cost-effective at fixed MOF IT of 14% and HF IT of 3.5%, regardless of age. PURPOSE: Osteoporosis represents a significant public health challenge in India, with an increasing economic burden due to the aging population. This study evaluated the cost-effectiveness of using fracture risk assessment tool (FRAX®)-based intervention thresholds (ITs) for managing osteoporosis with generic alendronate in Indian women. METHODS: A Markov microsimulation model, adapted to the Indian healthcare context, was used to simulate the costs and quality-adjusted life years (QALYs) associated with different treatment strategies. The one-time gross domestic product (GDP) per capita (estimated at INR 1,97,468/QALY gained) was used as the cost-effectiveness threshold. RESULTS: The model revealed that generic alendronate is cost-effective for major osteoporotic fracture (MOF) ITs beginning at age 60 years with full adherence-incremental cost-effectiveness ratio (ICER) of INR 102,151 per QALY gained, and age 65 with real-world adherence-ICER of INR 28,203 per QALY gained (conversion rate used is 1 US dollar (USD) = INR 83.97 and 1 EURO = INR 92.70). Hip fracture (HF) ITs showed similar cost-effectiveness at ages 60 (ICER of INR 67,144) and was the dominant strategy (i.e., more QALYs for lower costs) at ≥ 65 years. Fixed ITs of 14% for MOF and 3.5% for HF proved cost-effective across all age groups (dominant strategy for ages ≥ 65 years). Limitations of our study include the reliance on fracture incidence data from Singaporean Indians and variability in fracture prevalence across India. CONCLUSION: The results support the integration of FRAX®-based fixed ITs from the age of 50 years and age-based ones from the age of 65 years in India to optimize resource allocation and improve osteoporosis management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoporotic FracturesBone Density Conservation AgentsAlendronateOsteoporosis, PostmenopausalHumansFemaleCost-Benefit AnalysisMiddle AgedAgedMarkov ChainsQuality-Adjusted Life YearsIndiaHip FracturesRisk AssessmentDrugs, GenericDrug Costs

Stichwörter der Autor:innen

Cost effectivenessFRAXIndianIntervention thresholdsOsteoporosis

Substanzen

Bone Density Conservation AgentsAlendronateDrugs, Generic

Autor:innen und Institutionen

  • Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, Karnataka, India. drlakshminagendra@gmail.com.
  • Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. drlakshminagendra@gmail.com.
  • Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, 20, College Road, Academia, Singapore General Hospital, Singapore, 169856, Singapore. mchandran7@gmail.com.
  • DUKE-NUS Medical School, Singapore, Singapore. mchandran7@gmail.com.
  • Protein Research Chair, Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.
  • Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Förderung

  • Endocrine society of India

Zitieren

APA

Nagendra, L., Chandran, M., Reginster, J. Y., Bhadada, S. K., Bhattacharya, S., Dutta, D., & Hiligsmann, M. (2025). Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Indian women: a Markov microsimulation model analysis. Osteoporosis International, 36(2), 311-322. https://doi.org/10.1007/s00198-024-07328-6

Vancouver

Nagendra L, Chandran M, Reginster JY, Bhadada SK, Bhattacharya S, Dutta D, et al. Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Indian women: a Markov microsimulation model analysis. Osteoporosis International. 2025;36(2):311-322. doi:10.1007/s00198-024-07328-6

BibTeX
@article{Nagendra2025,
  author = {Nagendra, Lakshmi and Chandran, Manju and Reginster, Jean-Yves and Bhadada, Sanjay Kumar and Bhattacharya, Saptarshi and Dutta, Deep and Hiligsmann, Mickael},
  title = {Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Indian women: a Markov microsimulation model analysis},
  journal = {Osteoporosis International},
  year = {2025},
  volume = {36},
  number = {2},
  pages = {311--322},
  doi = {10.1007/s00198-024-07328-6}
}
Kostenlos starten →